Quantcast
Channel: Tracxn Blog
Viewing all articles
Browse latest Browse all 2659

Emmaus secures FDA panel backing for sickle cell drug, scraps $225M Generex deal – BioPharma Daily # 247

$
0
0

INTERESTING COMPANIES FOUND

RoverMed Biosciences (2016, Minnetonka) – Developing therapeutics for solid cancers using its Crystalline Ultra-Small Particle (CUSP) technology. Its CUSP technology can deliver the drugs into the cell nucleus regardless of cell’s location.

HIGHLIGHTS OF THE DAY

  • Mystery biotech Emmaus grabs groundbreaking FDA panel backing for sickle cell drug — after quietly scrapping $225M deal. Read More
  • Harpoon Therapeutics raises $45M Series B for taking Immuno-Onco drug to trials. Read More
  • NEJM paper buoys GW Pharma as it eyes FDA filing for cannabis drug Epidiolex. Read More
  • Promising Glaucoma trial results push Aerie Pharma 39% higher. Read More
  • Merck moves from amyloid to Tau, in-licenses Teijin Pharma’s antibody candidate. Read More

Viewing all articles
Browse latest Browse all 2659

Trending Articles